Portia Smallbone

Happy to share our work in Leukemia, showing that donor selection (specifically DPB1 mismatching) can be harnessed to measurably reduce relapse in high risk AML/MDS patients, without effect on GVHD. nature.com/articles/s4137… @UTMDAnderson #bmtsm #leusm

@Aljawai_Y Congratulations!

What a privilege it was to be part of Precision Oncology Saudi Summit 2026🇸🇦 #EventTroop #POSS2026 #PrecisionOncology #HealthcareInnovation possoncology.com

What a truly remarkable pair of award lectures at #Tandem26. Stella Davies gave a wonderful Mortimer Bortin lecture @CIBMTR & Jamie Ferrara giving a superb E Donall Thomas lecture @ASTCT. Congratulations to both.

Great to present our work from @MDAndersonNews using patient-reported outcomes to better capture the patient experience after allo-HCT. Multi-domain symptom burden can be persistent, even in those without GVHD. @ASTCT #Tandem2026 #bmtsm

Just out in @cytotherapy: MPC-based expansion and exofucosylation is safe but did not improve engraftment times. Negative studies matter too! #bmtsm isct-cytotherapy.org/article/S1465-…

In a study presented by our Dr. Yosra Aljawai, donor age is not associated with progression-free survival or overall survival in patients who received haploidentical transplantation since 2018. #ASH25 #EndCancer

Now at poster 6058 - persistent symptom burden in survivors of stem cell transplantation. despite cure; many patients have notable fatigue, sexual dysfunction and sleep disturbance - areas for future improvement! #ASH2025 #bmtsm #survivorship @MDAndersonNews

Our Dr. Portia Smallbone reported at #ASH25 that there are three archetypes for relapse after allogeneic stem cell transplantation in patients with FLT3-ITD positive acute myeloid leukemia: FLT3 persistence, loss and ITD/TKD change. Each type may require a specific treatment for best outcomes. @PortiaSmallbone #EndCancer

Enjoyed discussing donor age and haploidentical transplant at #ASH2025 @MDAndersonNews. Every patient has a donor and donor selection should be context dependent, not based on arbitrary donor age cutoffs! #bmtsm #amlsm

Very proud to present our work on clonal dynamics of relapse in FLT-ITD mutant AML post HCT. Three relapse archetypes emerging: FLT3 persistence, loss and ITD/TKD change - all with their own therapeutic implications. #ASH25 #amlsm #bmtsm @MDAndersonNews @sanamloghavi

Looking forward to it! @sanamloghavi @MDAndersonNews @ASH_hematology #ASH25

@BloodPortfolio @Aljawai_Y Congratulations @Aljawai_Y! Great to be a part of this @MDAndersonNews

Comparative outcomes of HSCT with posttransplant cyclophosphamide in older adults: the impact of donor type ow.ly/T2Oq50XjjV3 #healthservicesandoutcomes #transplantation

@KJClots Well done! Very important work 📣

Great to be involved in this manuscript highlighting the lasting effects of PE. From Crisis to Chronic: Rethinking Recovery after Pulmonary Emboli academic.oup.com/eurjpc/article…

ASCT vs CAR-T in CR for R/R DLBCL @TheEBMT #18ICML: no diff OS, PFS, relapse or NRM in propensity matched model. Important findings for areas in which CAR-T is not available. #lymsm #bmtsm

Plenary #3 #EHA2025 Very proud 🇦🇺 of @ALLGtrials randomized CAST trial Practice-changing study showing substantial reduction in GRFS, relapse-free survival & GvHD for PTCy in matched sibling donor allogeneic transplant Out in @NEJM nejm.org/doi/full/10.10… #bmtsm

a comprehensive report of the survival outcomes among 240 patients who underwent a transplant at the MD Anderson Cancer Center for acute myeloid leukemia AML or myelodysplastic syndrome with TP53 mutations over a 10-year period. ow.ly/Y03x50W7qaE #transplantation

@GMI_Canada @SickKidsNews @UofTNeuroSurge @ArjunChandran89 congrats chief

A brilliant, thoughtful and articulate #HumphriesLecture from our (soon-to-be-former) chief fellow, Arjun Chandran. Reflecting on his experience @SickKidsNews @UofTNeuroSurge

@HindRafei @lab_rezvani @MDAndersonNews Congratulations! Great work

Honored to present our work around the identification of #CREM as a regulatory checkpoint of CAR and cytokine signaling at #AACR25. Grateful to @lab_rezvani for her support over the years and to @MDAndersonNews for being the best place for #cancerresearch. Excited to advance this work and help make cancer history! Congratulations to all the speakers for stellar talks and thanks to our cochairs @sidichen and @DJPowellLab for an outstanding session!

Treatment options for cGvHD! #EBMT25 -Ruxolitinib -Ibrutinib -Axatilimab -Belumosudil Proper sequence? Combined or monotherapy? Best patient for each of it? Expecting results from de ongoing RCT! Thank you @Mohty_EBMT for a wonderful presentation @TheEBMT @TheEBMT_Trainee

Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703 #bmtsm @BMTCTN @sghmd @MediHumdani ascopubs.org/doi/10.1200/JC…